Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Oxford Sanofi-Aventis AstraZeneca |
---|---|
Information provided by: | University of Oxford |
ClinicalTrials.gov Identifier: | NCT00222573 |
COMMIT/CCS2 is a large randomised trial of the effects of clopidogrel plus Aspirin versus Aspirin alone in acute heart disease. Patients presenting within 24 hours of the onset of suspected acute MI were potentially eligible provided they were thought to have ST elevation or other ischaemic ECG abnormality with no clear indication for, or contraindication to, trial treatment. All patients were to be given 162 mg ASA daily and, in addition, 75 mg clopidogrel daily or matching placebo for 4 weeks or until prior discharge or death. (Patients were also randomised separately in a 2 X 2 factorial design between metoprolol versus placebo.) The two main study endpoints are death and the composite outcome of death, non-fatal reinfarction or stroke during the scheduled treatment period in hospital.
Condition | Intervention | Phase |
---|---|---|
Acute Myocardial Infarction |
Drug: clopidogrel and metoprolol |
Phase IV |
Study Type: | Interventional |
Study Design: | Double-Blind, Factorial Assignment, Placebo Control, Randomized, Safety/Efficacy Study, Treatment |
Official Title: | Clopidogrel Or Metoprolol in Myocardial Infarction Trial |
Estimated Enrollment: | 46000 |
Study Start Date: | July 1999 |
Estimated Study Completion Date: | February 2005 |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
China | |
Institute of Cadiovascular diseases, Fuwai hospital, Chinese academy of medical sciences | |
Beijing, China, 100037 | |
United Kingdom | |
Clinical Trial Service Unit and Epidemiological Studies Unit | |
Oxford, United Kingdom, OX3 7LF |
Study Chair: | Rory Collins, Msc | University of Oxford |
Study Chair: | Lisheng Liu, MD | Institute of cardiovascular diseases, Fuwai hospital, Chinese academy of medical sciences |
Study ID Numbers: | COMMIT-CCS2, H6RDCN0 |
Study First Received: | September 13, 2005 |
Last Updated: | May 4, 2006 |
ClinicalTrials.gov Identifier: | NCT00222573 History of Changes |
Health Authority: | China: Ministry of Health |
clopidogrel metoprolol myocardial infarction randomised trial |
Neurotransmitter Agents Heart Diseases Adrenergic Agents Myocardial Ischemia Vascular Diseases Cardiovascular Agents Ischemia Antihypertensive Agents Metoprolol Necrosis |
Aspirin Clopidogrel Metoprolol succinate Adrenergic beta-Antagonists Platelet Aggregation Inhibitors Adrenergic Antagonists Anti-Arrhythmia Agents Infarction Myocardial Infarction |
Neurotransmitter Agents Adrenergic Agents Molecular Mechanisms of Pharmacological Action Myocardial Ischemia Hematologic Agents Physiological Effects of Drugs Necrosis Pathologic Processes Therapeutic Uses Adrenergic beta-Antagonists Cardiovascular Diseases Anti-Arrhythmia Agents Myocardial Infarction Sympatholytics |
Heart Diseases Vascular Diseases Ischemia Cardiovascular Agents Metoprolol Antihypertensive Agents Pharmacologic Actions Autonomic Agents Clopidogrel Metoprolol succinate Platelet Aggregation Inhibitors Adrenergic Antagonists Peripheral Nervous System Agents Infarction |